← All financial models

Novartis (NVS) Financial Model

📊 Download Model

Three-statement Excel model · 14 quarters and 3 fiscal years of history · 10 quarters and 5 fiscal years of projections

current ✓ C13 recon ✓ C14 trace ✓ C15 terminals

About the NVS model

This three-statement Excel model covers Novartis AG (NVS): its income statement, balance sheet and cash flow statement. It holds 14 quarters and 3 fiscal years of history and 10 quarters and 5 fiscal years of projections.

Projected revenue is built from KPI drivers: Net sales built brand by brand: 28 disclosed brands on their own sequential growth rates, summing to five therapeutic areas, plus one explicit line for pipeline assets not yet launched, across 5 segments.

Beyond the income statement, the workbook has these sections: KPI Drivers, Balance Sheet, Cash Flow Statement, Core (non-IFRS) Reconciliation and Net Sales by Region (memo).

Model thesis: Entresto's US cliff against six ramping launches: FY2026E net sales +3.0% on guidance, +5.05% CAGR to 2030 at the bottom of management's band, and the out-years rest on one visible pipeline line

On October 19, 2026, the model passed checks C13 (every subtotal reconciles to the reported figure at $0), C14 (every projected revenue cell traces to a KPI driver row) and C15 (each driver ends in a rate, a count or a historical anchor, never a typed-in projected dollar level). It was last updated September 28, 2026.

History
14 quarters and 3 fiscal years
Projections
10 quarters and 5 fiscal years
KPI
Net sales built brand by brand: 28 disclosed brands on their own sequential growth rates, summing to five therapeutic areas, plus one explicit line for pipeline assets not yet launched
Segments
5
Units
USD in millions, except per share
Verified
Updated
File
Excel workbook (.xlsx), 224 KB
Access
Free account required: 3 different models a month at no charge, then $9 a month.

Income statement preview

Columns FY2023–FY2025 are actual results and FY2026E–FY2028E are our estimates. Figures were recalculated in Excel on September 28, 2026. USD in millions, except per share.

Income statement preview for NVS. USD in millions, except per share. Actual fiscal years followed by our estimates.
Income Statement
ActualEstimate
FY2023FY2024FY2025FY2026EFY2027EFY2028E
Net Sales - Cardiovascular, Renal and Metabolic$6,390$8,576$8,959$6,679$6,731$6,954
Net Sales - Immunology7,7989,29310,29310,74711,10111,361
Net Sales - Neuroscience3,6514,7505,9937,2478,1318,843
Net Sales - Oncology12,85114,29716,83017,86520,63122,564
Net Sales - Established Brands14,75013,40112,45713,62112,97812,456
Net Sales - Pipeline Assets Not Yet Launched00003021,254
Total Net Sales$45,440$50,317$54,532$56,159$59,874$63,433
Other Revenues$1,220$1,405$2,142$1,971$2,096$2,157
Total Revenue$46,660$51,722$56,674$58,130$61,969$65,590
Less: Cost of Goods Sold($12,472)($12,827)($13,699)($15,028)($16,236)($16,922)
Gross Profit$34,188$38,895$42,975$43,102$45,733$48,667
Less: Selling, General and Administration($12,517)($12,566)($13,248)($13,558)($14,749)($15,348)
Less: Research and Development(11,371)(10,022)(11,200)(11,978)(13,014)(13,511)
Other Income1,7721,1751,4601,7481,7971,902
Less: Other Expense(2,303)(2,938)(2,343)(2,279)(2,107)(2,164)
Total Operating Expenses and Other, net($24,419)($24,351)($25,331)($26,068)($28,072)($29,122)
Operating Income$9,769$14,544$17,644$17,034$17,661$19,546
Add: Depreciation, Amortisation and Impairments$8,277$6,069$5,325$5,532$5,633$5,440
EBITDA$18,046$20,613$22,969$22,566$23,294$24,986
Loss from Associated Companies($13)($38)($12)($11)($12)($12)
Less: Interest Expense(855)(1,006)(1,144)(1,735)(1,860)(1,860)
Other Financial Income and Expense222140(136)(117)(100)(100)
Income Before Taxes$9,123$13,640$16,352$15,171$15,689$17,574
Less: Income Taxes(551)(1,701)(2,385)(2,860)(2,589)(2,900)
Net Income from Continuing Operations$8,572$11,939$13,967$12,311$13,100$14,674
Net Income from Discontinued Operations (Sandoz)$6,282$0$0$0
of which: Sandoz result before the distribution gain422000
of which: gain on distribution of Sandoz Group AG5,860000
Net Income$14,854$11,939$13,967$12,311$13,100$14,674
Attributable to Shareholders of Novartis AG$14,850$11,941$13,984$12,326$13,116$14,690
Attributable to Non-Controlling Interests4(2)(17)(15)(16)(16)
Net Income, Attributed$14,854$11,939$13,967$12,311$13,100$14,674
Weighted Average Shares Outstanding - Basic (million)2,0772,0181,9391,9011,8781,857
Weighted Average Shares Outstanding - Diluted (million)2,0922,0351,9551,9131,8931,873
Basic Earnings per Share$7.15$5.92$7.21$6.48$6.99$7.91
Diluted Earnings per Share$7.10$5.87$7.15$6.44$6.93$7.84
Ratios & Assumptions
YoY Total Net Sales Growth10.7%8.4%3.0%6.6%5.9%
Gross Margin75.2%77.3%78.8%76.7%76.4%76.7%
Operating Margin21.5%28.9%32.4%30.3%29.5%30.8%
Net Margin32.7%23.7%25.6%21.9%21.9%23.1%
Effective Tax Rate6.0%12.5%14.6%18.9%16.5%16.5%

The full workbook adds 14 historical and 10 projected quarters, plus KPI Drivers · Balance Sheet · Cash Flow Statement · Core (non-IFRS) Reconciliation · Net Sales by Region (memo) — every subtotal a live formula, every projection traced to a driver.

Download the full NVS model (xlsx)3 free models a month with an account, then $9 a month

Novartis research

Aardvark Labs Capital Research has published 5 reports on Novartis (NVS). The latest is the Q3 2026 Earnings Recap, published October 31, 2026, rated Hold.

Novartis Raises Its Profit Guide in the Quarter Two of Its Three Big Bets Failed

All NVS research →

Methodology

Every projected revenue cell traces to a KPI/driver row (C14). Terminal driver cells are rates, counts, or historical anchors — never typed-in projected dollar levels (C15). Every subtotal-vs-reported reconciliation row ties to $0 (C13). Each model is written per-ticker against its actual schema — no cloning, no level-input shortcuts.